Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer

doi:10.3760/cma.j.cn371439-20220816-00145

Abstract

Abstract:

Immunotherapy, especially immune checkpoint inhibitor, has revolutionized the treatment mode of advanced non-small cell lung cancer. The predictive effect of programmed death-ligand 1 and tumor mutation burden for treatment response has been fully proved. Neither of which can avoid some problems, including tumor heterogeneity, inconsistent detection methods and identification standards. The studies have found that some novel biomarkers are related to the efficacy of immunotherapy, such as mismatch repair deficiency and microsatellite instability, driver gene mutation, routine peripheral blood biomarkers, circulating tumor cells, circulating tumor DNA and so on. Further research on the predictive value of biomarkers in tumor tissue and peripheral blood in immunotherapy of advanced non-small cell lung cancer can provide a reference for instituting clinical treatment plan.

Key words: Carcinoma, non-small-cell lung, Immune checkpoint inhibitors, Biomarker

Lei Yan, Zhang Gehong. Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(12): 739-744.

References 38

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002. doi: 10.1016/j.jncc.2022.02.002
[2]	罗宏, 殷红, 胡广越, 等. 血清炎性标志物对非小细胞肺癌免疫治疗的预测价值[J]. 国际肿瘤学杂志, 2022, 49(3): 177-180. DOI: 10.3760/cma.j.cn371439-20211115-00030. doi: 10.3760/cma.j.cn371439-20211115-00030
[3]	Bie F, Tian H, Sun N, et al. Research progress of anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC[J]. Front Oncol, 2022, 12: 769124. DOI: 10.3389/fonc.2022.769124. doi: 10.3389/fonc.2022.769124
[4]	Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune check-point inhibition in non-small cell lung cancer (NSCLC)[J]. Cancer, 2020, 126(2): 260-270. DOI: 10.1002/cncr.32468. doi: 10.1002/cncr.32468
[5]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year out-comes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50[J]. J Clin Oncol, 2021, 39(21): 2339-2349. DOI: 10.1200/JCO.21.00174. doi: 10.1200/JCO.21.00174
[6]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemo-therapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi: 10.1016/S0140-6736(18)32409-7
[7]	Velcheti V, Hu X, Yang L, et al. Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with ≥50% expression of programmed cell death-ligand 1[J]. Front Oncol, 2022, 12: 834761. DOI: 10.3389/fonc.2022.834761. doi: 10.3389/fonc.2022.834761
[8]	Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update[J]. ESMO Open, 2021, 6(5): 100273. DOI: 10.1016/j.esmoop.2021.100273. doi: 10.1016/j.esmoop.2021.100273
[9]	Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade mono-therapy in clinical trials[J]. Ther Adv Med Oncol, 2020, 12: 1758835920937612. DOI: 10.1177/1758835920937612. doi: 10.1177/1758835920937612
[10]	Honrubia-Peris B, Garde-Noguera J, García-Sánchez J, et al. Soluble biomarkers with prognostic and predictive value in advanced non-small cell lung cancer treated with immunotherapy[J]. Cancers (Basel), 2021, 13(17): 4280. DOI: 10.3390/cancers13174280. doi: 10.3390/cancers13174280
[11]	Guven DC, Sahin TK, Dizdar O, et al. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives[J]. Biomark Med, 2020, 14(14): 1383-1392. DOI: 10.2217/bmm-2020-0310. doi: 10.2217/bmm-2020-0310 pmid: 33064030
[12]	Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers[J]. J Clin Oncol, 2019, 37(12): 992-1000. DOI: 10.1200/JCO.18.01042. doi: 10.1200/JCO.18.01042 pmid: 30785829
[13]	Kim ES, Velcheti V, Mekhail T, et al. Blood-based tumor muta-tional burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial[J]. Nat Med, 2022, 28(5): 939-945. DOI: 10.1038/s41591-022-01754-x. doi: 10.1038/s41591-022-01754-x
[14]	Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 661-674. DOI: 10.1001/jamaoncol.2020.0237. doi: 10.1001/jamaoncol.2020.0237 pmid: 32271377
[15]	Otoshi T, Nagano T, Tachihara M, et al. Possible biomarkers for cancer immunotherapy[J]. Cancers (Basel), 2019, 11(7): 935. DOI: 10.3390/cancers11070935. doi: 10.3390/cancers11070935
[16]	Giustini N, Bazhenova L. Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs)[J]. Lung Cancer (Auckl), 2021, 12: 21-34. DOI: 10.2147/LCTT.S235102. doi: 10.2147/LCTT.S235102
[17]	Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients[J]. Cancer Med, 2018, 7(3): 746-756. DOI: 10.1002/cam4.1372. doi: 10.1002/cam4.1372
[18]	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevaci-zumab and chemotherapy in non-small-cell lung cancer (IMpower 150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. DOI: 10.1016/S2213-2600(19)30084-0. doi: 10.1016/S2213-2600(19)30084-0
[19]	Arrieta O, Barrón F, Ramírez-Tirado LA, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial[J]. JAMA Oncol, 2020, 6(6): 856-864. DOI: 10.1001/jamaoncol.2020.0409. doi: 10.1001/jamaoncol.2020.0409 pmid: 32271354
[20]	West HJ, McCleland M, Cappuzzo F, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase Ⅲ IMpower150 trial[J]. J Immunother Cancer, 2022, 10(2): e003027. DOI: 10.1136/jitc-2021-003027. doi: 10.1136/jitc-2021-003027
[21]	Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, et al. Biomarkers of immune checkpoint inhibitors in non-small cell lung cancer: beyond PD-L1[J]. Clin Lung Cancer, 2021, 22(5): 381-389. DOI: 10.1016/j.cllc.2021.03.006. doi: 10.1016/j.cllc.2021.03.006 pmid: 33875382
[22]	Zhang N, Jiang J, Tang S, et al. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis[J]. Int Immunopharmacol, 2020, 85: 106677. DOI: 10.1016/j.intimp.2020.106677. doi: 10.1016/j.intimp.2020.106677
[23]	Yang T, Hao L, Yang X, et al. Prognostic value of derived neutro-phil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis[J]. BMJ Open, 2021, 11(9): e049123. DOI: 10.1136/bmjopen-2021-049123. doi: 10.1136/bmjopen-2021-049123
[24]	Lim JU, Kang HS, Yeo CD, et al. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors[J]. J Thorac Dis, 2021, 13(5): 2824-2832. DOI: 10.21037/jtd-20-3416. doi: 10.21037/jtd-20-3416 pmid: 34164174
[25]	Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor out-comes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(3): 351-357. DOI: 10.1001/jamaoncol.2017.4771. doi: 10.1001/jamaoncol.2017.4771 pmid: 29327044
[26]	Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964. DOI: 10.1002/jcla.22964. doi: 10.1002/jcla.22964
[27]	Shi Y, Liu X, Liu J, et al. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments[J]. Transl Lung Cancer Res, 2021, 10(12): 4477-4493. DOI: 10.21037/tlcr-21-710. doi: 10.21037/tlcr-21-710
[28]	Liu N, Jiang A, Zheng X, et al. Prognostic nutritional index iden-tifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors[J]. J Cancer, 2021, 12(10): 2960-2967. DOI: 10.7150/jca.55936. doi: 10.7150/jca.55936 pmid: 33854596
[29]	Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J]. Cancer Immunol Immunother, 2020, 69(9): 1813-1822. DOI: 10.1007/s00262-020-02585-w. doi: 10.1007/s00262-020-02585-w pmid: 32350592
[30]	Johannet P, Sawyers A, Qian Y, et al. Baseline prognostic nutri-tional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer[J]. J Immunother Cancer, 2020, 8(2): e001674. DOI: 10.1136/jitc-2020-001674. doi: 10.1136/jitc-2020-001674
[31]	Boutsikou E, Domvri K, Hardavella G, et al. Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice[J]. Ther Adv Med Oncol, 2018, 10: 1758835918768238. DOI: 10.1177/1758835918768238. doi: 10.1177/1758835918768238
[32]	Agulló-Ortuño MT, Gómez-Martín Ó, Ponce S, et al. Blood pre-dictive biomarkers for patients with non-small-cell lung cancer associated with clinical response to nivolumab[J]. Clin Lung Cancer, 2020, 21(1): 75-85. DOI: 10.1016/j.cllc.2019.08.006. doi: S1525-7304(19)30255-4 pmid: 31562055
[33]	Pawlikowska P, Faugeroux V, Oulhen M, et al. Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies[J]. J Thorac Dis, 2019, 11(Suppl 1): S45-S56. DOI: 10.21037/jtd.2018.12.80. doi: 10.21037/jtd.2018.12.80
[34]	Ikeda M, Koh Y, Teraoka S, et al. Longitudinal evaluation of PD-L1 expression on circulating tumor cells in non-small cell lung cancer patients treated with nivolumab[J]. Cancers (Basel), 2021, 13(10): 2290. DOI: 10.3390/cancers13102290. doi: 10.3390/cancers13102290
[35]	Guibert N, Delaunay M, Lusque A, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab[J]. Lung Cancer, 2018, 120: 108-112. DOI: 10.1016/j.lungcan.2018.04.001. doi: S0169-5002(18)30317-9 pmid: 29748004
[36]	Janning M, Kobus F, Babayan A, et al. Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors[J]. Cancers (Basel), 2019, 11(6): 835. DOI: 10.3390/cancers11060835. doi: 10.3390/cancers11060835
[37]	Ricciuti B, Jones G, Severgnini M, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2021, 9(3): e001504. DOI: 10.1136/jitc-2020-001504. doi: 10.1136/jitc-2020-001504
[38]	Wang H, Zhou F, Qiao M, et al. The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Front Oncol, 2021, 11: 671874. DOI: 10.3389/fonc.2021.671874. doi: 10.3389/fonc.2021.671874